Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Multicenter, Dose-escalation and Cohort Expansion Study of OKN4395, a Triple Antagonist of EP2, EP4, and DP1 Prostanoid Receptors, as Monotherapy and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors

NCT06789172 is registered in ClinicalTrials.gov with Epkin as lead sponsor.

NCT NCT06789172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06789172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Multicenter, Dose-escalation and Cohort Expansion Study of OKN4395, a Triple Antagonist of EP2, EP4, and DP1 Prostanoid Receptors, as Monotherapy and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors
Lead sponsor
Epkin
Phase
Phase 1
Overall status
Recruiting
Start date
January 23, 2025
Completion date
September 30, 2028
Enrollment
146 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer (crc), dedifferentiated liposarcoma, gastric / gastroesophageal junction adenocarcinoma, gastric cancer (gc), gastric cancer adenocarcinoma metastatic, hnscc, leiomyosarcoma, leiomyosarcoma (lms), myxofibrosarcoma (mfs), non small cell lung cancer, nsclc, sarcoma, solid tumours, solitary fibrous tumors, undifferentiated pleomorphic sarcoma (ups)